Marı́a Varela
A5023733918- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Liver Disease and Transplantation
- Pancreatic and Hepatic Oncology Research
- Hepatitis B Virus Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Liver physiology and pathology
- Cancer, Lipids, and Metabolism
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Treatments and Mutations
- Organ Transplantation Techniques and Outcomes
- Renal cell carcinoma treatment
- Cancer Treatment and Pharmacology
- Genetic and Kidney Cyst Diseases
- Alcohol Consumption and Health Effects
- Pancreatitis Pathology and Treatment
- COVID-19 and healthcare impacts
- Vascular Malformations and Hemangiomas
- Plant Physiology and Cultivation Studies
- Glioma Diagnosis and Treatment
- Diet, Metabolism, and Disease
- Cancer Mechanisms and Therapy
- Hepatitis Viruses Studies and Epidemiology
Central University Hospital of Asturias
2016-2025
Universidad de Oviedo
2009-2025
Humanitas University
2023-2025
IRCCS Humanitas Research Hospital
2023-2025
Centro de Investigación Biomédica en Red de Cáncer
2024
Instituto de Investigación Biomédica de Salamanca
2024
Hôpital Avicenne
2023
Instituto de Investigación Sanitaria del Principado de Asturias
2021-2023
Assistance Publique – Hôpitaux de Paris
2023
Hôpitaux Universitaires Paris-Ouest
2023
This study prospectively evaluates the accuracy of contrast-enhanced ultrasound (CEUS) and dynamic magnetic resonance imaging (MRI) for diagnosis nodules 20 mm or smaller detected during (US) surveillance. We included 89 patients with cirrhosis [median age, 65 years; male 53, hepatitis C virus 68, Child-Pugh A 80] without prior hepatocellular carcinoma (HCC) in whom US a small solitary nodule (mean diameter, 14 mm). Hepatic MRI, CEUS, fine-needle biopsy (gold standard) (FNB) were performed...
BackgroundA single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion regimen termed STRIDE (Single Tremelimumab Regular Interval Durvalumab), showed encouraging clinical activity and safety in a phase 2 trial unresectable hepatocellular carcinoma.MethodsIn this global, open-label, 3 trial, the majority patients we enrolled with carcinoma no previous systemic treatment were randomly assigned...
Evaluation of response to treatment is a key aspect in cancer therapy. Response Criteria Solid Tumors (RECIST) are used most oncology trials, but those criteria evaluate only unidimensional tumor measurements and disregard the extent necrosis, which target all effective locoregional therapies. Therefore, European Association for Study Liver (EASL) guidelines recommended that assessment should incorporate reduction viable burden. The current report provides an agreement/concordance between...
Surgical resection and liver transplantation offer a 5-year survival greater than 70% in patients with hepatocellular carcinoma, but the high recurrence rate impairs long-term outcome after resection. Pathological data such as vascular invasion detection of additional nodules predict divide into low risk profile. Based on this, we proposed salvage transplant to resected whom pathology evidenced even absence proven residual disease. From January 1995 August 2003 have evaluated 1,638 patients....
Regorafenib is one option for second-line treatment of hepatocellular carcinoma (HCC), improving overall survival (OS) sorafenib-tolerant patients who develop progression. We aim to evaluate the safety and outcomes regorafenib as HCC recurrence after liver transplantation (LT). This a retrospective, multicenter, international study including regorafenib-treated LT (2015-2018), with analysis baseline characteristics evolutionary events during sorafenib/regorafenib treatment. Twenty-eight (57...
To evaluate the safety and efficacy of selective internal radiation therapy (SIRT) in combination with a PD-1 inhibitor patients unresectable hepatocellular carcinoma (uHCC) liver-only disease ineligible for chemoembolization.NASIR-HCC is single-arm, multicenter, open-label, phase 2 trial that recruited from 2017 to 2019 who were naïve immunotherapy had tumors BCLC B2 substage (single or multiple beyond up-to-7 rule), unilobar segmental lobar portal vein invasion (PVI); no extrahepatic...
The clinical benefit of sorafenib in patients with hepatocellular carcinoma (HCC) has been undervalued due to the absence complete responses, even though who develop early dermatologic reactions have shown a positive outcome. In addition, is described as an antiangiogenic drug, but it also acts on immunological cells. Thus, goal this study was assess response rate retrospective cohort HCC treated and describe profile achieve for identifying factors related event their connection sorafenib....
The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures been interrupted delayed because COVID-19 pandemic.An international survey impact on clinical practice trials from March 2020 June 2020, as first phase a multicentre, international, observational project. focus was hepatocellular carcinoma intrahepatic...
El carcinoma hepatocelular (CHC) es la neoplasia primaria de hígado más frecuente y una las causas muerte común en los pacientes afectos cirrosis hepática. Simultáneamente al reconocimiento relevancia clínica esta neoplasia, últimos años han aparecido novedades importantes el diagnóstico, evaluación pronóstica y, especialmente, tratamiento del CHC. Por tal motivo, desde Asociación Española para Estudio Hígado (AEEH) se ha impulsado necesidad actualizar guías práctica clínica, invitando nuevo...
Cerebrolysin (Cere) is a compound with neurotrophic activity shown to be effective in Alzheimer's disease earlier trials. The efficacy and safety of three dosages Cere were investigated this randomized, double‐blind, placebo‐controlled, study. Two hundred seventy‐nine patients enrolled (69 10 ml; 70 30 71 60 ml 69 placebo). Patients received iv infusions 10, 30, or placebo 5 days/week for the first 4 weeks thereafter, two per week 8 weeks. Effects on cognition clinical global impressions...
Although alcohol cessation is the only effective treatment for alcohol-related liver disease, few data exist concerning its influence on risk of hepatocellular carcinoma (HCC). We aimed to evaluate effect abstinence incidence HCC in patients with cirrhosis.We studied 727 cirrhosis (247 compensated disease and 480 previous decompensation) who were included a surveillance program early detection prospectively followed. Baseline clinical biological parameters consumption during follow-up...